Nancy L. Nadon

TL;DR: It is reported that rapamycin, an inhibitor of the mTOR pathway, extends median and maximal lifespan of both male and female mice when fed beginning at 600 days of age.

TL;DR: Evaluation of rapamycin's effects on mice is likely to help delineate the role of the mammalian target ofRapamycin complexes in the regulation of aging rate and age-dependent diseases and may help to guide a search for drugs that retard some or all of the diseases of aging.

TL;DR: It is reported here that many forms of age‐dependent change, including alterations in heart, liver, adrenal glands, endometrium, and tendon, as well as age-dependent decline in spontaneous activity, occur more slowly in rapamycin‐treated mice, suggesting strongly thatRapamycin retards multiple aspects of aging in mice, in addition to any beneficial effects it may have on neoplastic disease.

TL;DR: Some of the endocrine and metabolic changes seen in diet‐restricted mice are not seen in mice exposed toRapamycin, and the pattern of expression of hepatic genes involved in xenobiotic metabolism is also quite distinct in rapamycin‐treated and diet‐ restricted mice, suggesting that these two interventions for extending mouse lifespan differ in many respects.

TL;DR: New pharmacological models for exploring processes that regulate the timing of aging and late‐life diseases are provided, and in particular for testing hypotheses about sexual dimorphism in aging and health are tested.